FRA:RHO - Deutsche Boerse Ag - CH0012032113 - Common Stock - Currency: EUR
Taking everything into account, RHO scores 6 out of 10 in our fundamental rating. RHO was compared to 53 industry peers in the Pharmaceuticals industry. RHO gets an excellent profitability rating and is at the same time showing great financial health properties. RHO is valued correctly, but it does not seem to be growing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 8.13% | ||
ROE | 26.06% | ||
ROIC | 22.12% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 33.2% | ||
PM (TTM) | 13.68% | ||
GM | 73.91% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.98 | ||
Debt/FCF | 2.3 | ||
Altman-Z | 3.94 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.48 | ||
Quick Ratio | 1.2 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 14.6 | ||
Fwd PE | 13.18 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 14.72 | ||
EV/EBITDA | 9.9 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 3.71% |
FRA:RHO (7/25/2025, 7:00:00 PM)
293.8
-5.6 (-1.87%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 3.71% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 14.6 | ||
Fwd PE | 13.18 | ||
P/S | 3.67 | ||
P/FCF | 14.72 | ||
P/OCF | 11.05 | ||
P/B | 6.99 | ||
P/tB | 33.71 | ||
EV/EBITDA | 9.9 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 8.13% | ||
ROE | 26.06% | ||
ROCE | 26.86% | ||
ROIC | 22.12% | ||
ROICexc | 28.73% | ||
ROICexgc | 50.83% | ||
OM | 33.2% | ||
PM (TTM) | 13.68% | ||
GM | 73.91% | ||
FCFM | 24.94% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.98 | ||
Debt/FCF | 2.3 | ||
Debt/EBITDA | 1.33 | ||
Cap/Depr | 146.33% | ||
Cap/Sales | 8.28% | ||
Interest Coverage | 17.54 | ||
Cash Conversion | 85.47% | ||
Profit Quality | 182.25% | ||
Current Ratio | 1.48 | ||
Quick Ratio | 1.2 | ||
Altman-Z | 3.94 |